Comprehensive Review Published in the Peer-Reviewed Journal, Clinical Pharmacology and Therapeutics
ATLANTA, GA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced the publication of a manuscript entitled “HIV/AIDS Vaccines: 2018,” authored by Harriet L. Robinson, PhD, GeoVax’s Director of HIV Vaccines and Chief Scientific Officer Emeritus. The paper is published in the peer-reviewed journal Clinical Pharmacology & Therapeutics, a journal of the American Society for Clinical Pharmacology & Therapeutics (ASCPT), and can be viewed at https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1208.
In the article, Dr. Robinson provides a comprehensive review of progress toward development of an HIV/AIDS vaccine, including key challenges and lessons learned from completed efficacy trials.
Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, commented, “Dr. Robinson’s review is an important reminder of the daunting task of HIV vaccine development and the numerous scientific contributions made by many people and institutions. Despite development of effective antiretroviral therapies (ART), only 49% and 48% of people living with HIV in the U.S. and worldwide, respectively, have drug-controlled infections. Patients without drug-controlled infections not only develop AIDS but actively spread the infection. This indicates that, for elimination of HIV, there is a need for an effective vaccine to be added to the arsenal of ART. Only with a demonstrated, effective HIV/AIDS vaccine can people worldwide avoid the infection, ongoing health risks and societal impact resulting from this disease. GeoVax is proud to be a leader in the effort for developing a vaccine for the clade B subtype of HIV prevalent in the Western Hemisphere, Europe and Japan. Our vaccine, GOVX-B11, is currently progressing in human clinical trials with the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).”
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
GeoVax Labs, Inc.